Can Commun Dis Rep. 2020 May 7;46(5):112-118. doi: 10.14745/ccdr.v46i05a02.
The ability to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, is a foundational component of Canada's containment and mitigation strategies. Laboratory confirmation of COVID-19 cases allows the appropriate clinical management and public health interventions. Whether the local goal is containment or mitigation will depend on local epidemiology of the pandemic. The Respiratory Virus Infections Working Group of the Canadian Public Health Laboratory Network has developed comprehensive Best Practice Guidelines for detection of SARS-CoV-2. Best practices for specimen collection, transportation, testing and biosafety are addressed from the perspective of Canadian public health laboratories to ensure a consistent approach across the country: Population-based testing for COVID-19 should initially be carried out for surveillanceNasopharyngeal swab is the specimen of choice for routine testingNucleic acid amplification tests (such as real-time reverse transcription polymerase chain reaction) are the method of choice for routine testing of SARS-CoV-2The decentralization of nucleic acid amplification testing for COVID-19 to hospital or other high complexity medical laboratories should be promoted to increase test capacity and meet increased demandsIn the early stages of the pandemic, positive (approximately 10-20) and negative (approximately 50) tests by a provincial laboratory require confirmation at the National Microbiology LaboratoryCo-circulation of other viral agents associated with influenza-like Illnesses (e.g. influenza A and B and respiratory syncytial virus) should be monitored as capacity permits, as part of ongoing surveillanceOnce validated, serological testing may be utilized for assessing the presence/absence of immune response to the SARS-CoV-2 at either the population or individual level for select indications, but is likely to be of limited utility in diagnosis of acute COVID-19 illness These recommendations will be updated as new information becomes available.
检测严重急性呼吸综合征冠状病毒2(SARS-CoV-2,即COVID-19的病原体)的能力是加拿大遏制和缓解策略的一个基本组成部分。对COVID-19病例进行实验室确认有助于进行适当的临床管理和公共卫生干预。当地的目标是遏制还是缓解将取决于该流行病的当地流行病学情况。加拿大公共卫生实验室网络的呼吸道病毒感染工作组已制定了检测SARS-CoV-2的全面最佳实践指南。从加拿大公共卫生实验室的角度阐述了标本采集、运输、检测和生物安全的最佳实践,以确保全国采用一致的方法:
应对COVID-19进行基于人群的检测,最初应进行监测
鼻咽拭子是常规检测的首选标本
核酸扩增检测(如实时逆转录聚合酶链反应)是SARS-CoV-2常规检测的首选方法
应推动将COVID-19核酸扩增检测下放至医院或其他高复杂性医学实验室,以提高检测能力并满足不断增加的需求
在疫情早期,省级实验室进行的阳性(约10 - 20份)和阴性(约50份)检测需要在国家微生物实验室进行确认
应在能力允许的情况下,监测与流感样疾病相关的其他病毒病原体(如甲型和乙型流感病毒以及呼吸道合胞病毒)的共同传播情况,作为持续监测的一部分
一旦经过验证,血清学检测可用于在人群或个体层面评估针对SARS-CoV-2的免疫反应的存在与否,以用于特定指征,但在诊断急性COVID-19疾病方面可能效用有限
这些建议将随着新信息的出现而更新。